Compare Dishman Pharma with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs SUN PHARMA - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA SUN PHARMA DISHMAN PHARMA/
SUN PHARMA
 
P/E (TTM) x 25.1 87.6 28.7% View Chart
P/BV x 3.3 3.7 89.6% View Chart
Dividend Yield % 0.7 0.6 116.7%  

Financials

 DISHMAN PHARMA   SUN PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
SUN PHARMA
Mar-20
DISHMAN PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs374484 77.3%   
Low Rs129315 40.9%   
Sales per share (Unadj.) Rs197.8136.9 144.5%  
Earnings per share (Unadj.) Rs21.217.5 121.5%  
Cash flow per share (Unadj.) Rs34.726.0 133.5%  
Dividends per share (Unadj.) Rs2.004.00 50.0%  
Dividend yield (eoy) %0.81.0 79.4%  
Book value per share (Unadj.) Rs179.9188.7 95.4%  
Shares outstanding (eoy) m80.692,399.26 3.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.32.9 43.6%   
Avg P/E ratio x11.922.9 51.8%  
P/CF ratio (eoy) x7.215.4 47.2%  
Price / Book Value ratio x1.42.1 66.0%  
Dividend payout %9.422.9 41.1%   
Avg Mkt Cap Rs m20,306958,864 2.1%   
No. of employees `0000.817.8 4.7%   
Total wages/salary Rs m5,35563,624 8.4%   
Avg. sales/employee Rs Th19,252.718,490.6 104.1%   
Avg. wages/employee Rs Th6,459.53,582.6 180.3%   
Avg. net profit/employee Rs Th2,064.12,357.6 87.6%   
INCOME DATA
Net Sales Rs m15,961328,375 4.9%  
Other income Rs m2656,360 4.2%   
Total revenues Rs m16,226334,735 4.8%   
Gross profit Rs m4,10369,898 5.9%  
Depreciation Rs m1,09120,528 5.3%   
Interest Rs m9443,027 31.2%   
Profit before tax Rs m2,33452,702 4.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m0-2,606 0.0%   
Tax Rs m6248,228 7.6%   
Profit after tax Rs m1,71141,868 4.1%  
Gross profit margin %25.721.3 120.8%  
Effective tax rate %26.715.6 171.2%   
Net profit margin %10.712.8 84.1%  
BALANCE SHEET DATA
Current assets Rs m11,018316,542 3.5%   
Current liabilities Rs m9,517157,064 6.1%   
Net working cap to sales %9.448.6 19.4%  
Current ratio x1.22.0 57.4%  
Inventory Days Days11088 126.2%  
Debtors Days Days35105 33.3%  
Net fixed assets Rs m16,304243,102 6.7%   
Share capital Rs m1612,399 6.7%   
"Free" reserves Rs m12,907450,245 2.9%   
Net worth Rs m14,516452,645 3.2%   
Long term debt Rs m4,18920,289 20.6%   
Total assets Rs m29,805682,525 4.4%  
Interest coverage x3.518.4 18.9%   
Debt to equity ratio x0.30 643.9%  
Sales to assets ratio x0.50.5 111.3%   
Return on assets %8.96.6 135.4%  
Return on equity %11.89.2 127.4%  
Return on capital %17.511.2 156.1%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95274,219 6.7%   
Fx outflow Rs m69727,964 2.5%   
Net fx Rs m4,25546,255 9.2%   
CASH FLOW
From Operations Rs m2,78665,548 4.3%  
From Investments Rs m-1,529-25,888 5.9%  
From Financial Activity Rs m-941-57,151 1.6%  
Net Cashflow Rs m316-13,857 -2.3%  

Share Holding

Indian Promoters % 61.4 63.7 96.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 5.1 72.1%  
FIIs % 12.7 23.0 55.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 8.3 266.3%  
Shareholders   46,261 133,026 34.8%  
Pledged promoter(s) holding % 35.8 0.5 6,747.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   FDC  UNICHEM LAB  DR. REDDYS LAB  ELDER PHARMA  ALEMBIC  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Falls 471 Points, Nifty Ends Below 14,700; Tata Steel & JSW Steel Top Losers(Closing)

Indian share markets witnessed selling pressure throughout the day today and ended lower.

Related Views on News

SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)

Dec 11, 2020 | Updated on Dec 11, 2020

Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS